Prescription Drug Diltiazem Hydrochloride Recalled for Manufacturing Impurity
Glenmark Pharmaceuticals is recalling 5,232 bottles of Diltiazem Hydrochloride Extended-Release Capsules nationwide due to an impurity that exceeds FDA safety limits. Patients currently taking this medication should contact their pharmacist or doctor.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall involving a manufacturing defect that resulted in a potentially harmful impurity above the FDA's interim safety limit. No illnesses or injuries have been reported, making this a theoretical risk-of-harm scenario. Per the severity rubric, risk-of-harm products with no reported injury are classified as High (3).
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling Diltiazem Hydrochloride Extended-Release Capsules 60 mg (Lot #17222544, expiration 11/30/2024) distributed nationwide. The recall affects approximately 5,232 bottles.
The recall was initiated due to a manufacturing quality deviation (cGMP violation): the presence of the impurity N-nitroso-Desmethyl-Diltiazem above the FDA's recommended interim limit. This impurity resulted from manufacturing conditions that did not meet current Good Manufacturing Practice standards.
Diltiazem is a prescription medication used to treat certain heart conditions. All patients who received this medication from the recalled lot may be affected.
Consumers who are currently taking this medication should contact their pharmacist or healthcare provider before making any changes to their treatment regimen. Do not stop taking the medication without medical guidance. Patients may ask their pharmacist about alternative sources of diltiazem that are not affected by this recall.
The recalled product
- Product
- DILTIAZEM HYDROCHLORIDE (DILTIAZEM HYDROCHLORIDE)
- Brand
- DILTIAZEM HYDROCHLORIDE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug — Prescription Medication
- Hazard
- impurity
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 17222544
- Exp 11/30/2024.
UPCs (3)
- 0316714555010
- 0316714553016
- 0316714554013
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DILTIAZEM HYDROCHLORIDE
- HighGlenmark Diltiazem Extended-Release Capsules recalled for manufacturing deviations
FDA (Drugs) · 2025-04-16
- HighDiltiazem Hydrochloride Capsules Recalled Due to Nitrosamine Impurity
FDA (Drugs) · 2024-12-11
- HighDiltiazem extended-release capsules recalled for manufacturing impurity
FDA (Drugs) · 2024-12-11
- HighDiltiazem Hydrochloride Extended-Release Capsules Recalled for Manufacturing Impurity
FDA (Drugs) · 2024-12-11
- HighDiltiazem Hydrochloride Capsules Recalled Due to Manufacturing Impurity
FDA (Drugs) · 2024-12-11
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27